Activatable Antibody Purification for Clipped Variant Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Monoclonal antibody compositions face challenges with product aggregation, leading to lower yields and potential safety issues due to the formation of clipped variants that indiscriminately bind to healthy cells, reducing the dose available for target tissues and increasing immunogenicity.
Innovation Solution
A process involving hydrophobic chromatography is used to separate intact activatable antibodies from clipped variants, achieving high purity and yield by leveraging differences in hydrophobic interactions, thereby reducing the amount of clipped impurity and other contaminants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If structural modifications are made to improve safety and efficacy of antibody-based therapeutics, then therapeutic performance is improved, but manufacturing challenges increase
Solution Approach 1:
The antibody molecule is segmented into distinct functional domains: a stable core structure and a separately expressed prodomain containing the masking moiety and cleavable moiety. This segmentation allows the core antibody to be manufactured with standard, well-established processes while the prodomain can be independently optimized and controlled, thereby improving both therapeutic performance and manufacturability.
Solution Approach 2:
The prodomain (containing masking and cleavable moieties) is extracted as a separate expressible element from the core antibody structure. This extraction enables independent purification and quality control of the core antibody product, reducing manufacturing complexity while maintaining the ability to achieve improved safety and efficacy through the separate prodomain component.
2Reliability
If activatable antibody structures are used to reduce off-target binding, then safety is improved, but clipped variants may still bind indiscriminately to healthy cells
Solution Approach 1:
The masking moiety is localized specifically to the prodomain region of the antibody structure, leaving the core antibody binding regions unaffected. This local quality control ensures that only the intended activatable mechanism is modified, maintaining high specificity for target tissues while providing safety through the localized masking function that prevents premature off-target binding.
Solution Approach 2:
The masking moiety performs a preliminary protective action by blocking the antigen-binding sites before the antibody reaches the target tissue. This preliminary action prevents premature activation and off-target binding in circulation, while the designed cleavable moiety ensures that this masking is removed only at the intended site of action, thereby resolving the contradiction between safety and off-target binding.
3Ease of manufacture
If standard purification methods are used, then manufacturing simplicity is maintained, but clipped variants and aggregates are not effectively removed
Solution Approach 1:
The purification process exploits parameter changes in the prodomain-antibody complex: the prodomain contains hydrophobic regions that change their binding characteristics under specific chromatographic conditions. By adjusting chromatography parameters (such as hydrophobic interaction chromatography conditions), the prodomain can be selectively retained or eluted, enabling effective separation of clipped variants and aggregates from the intact activatable antibody while maintaining manufacturing simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process effectively purifies activatable antibodies, ensuring high levels of intact antibodies with minimal clipped variants, enhancing therapeutic efficacy and safety by minimizing off-target binding and aggregation.
Implementation Method 1
a stationary phase that comprises a support matrix and hydrophobic ligands bound thereto
Data Source
AI summary
The invention provides a composition including an intact activatable antibody and a clipped variant thereof, methods of separating clipped variants of intact activatable antibodies from intact activatable antibodies and related methods including methods for determining or monitoring a relative percentage of an activatable antibody and a clipped variant thereof during a composition production process.